Moderna Inc (MRNA) - Company Sales

The economic moat of Moderna, Inc. (MRNA) has been temporarily weakened due to declining demand for COVID-19 vaccines and regulatory complexities. The company's commercial revenue level on GURU.Markets reflects current price action, where the indicator remains at 2.52. Growth is driven by the creation of an AI drug factory for cancer treatment and genetics. Premium margins are sustained by the strict patenting of breakthrough developments.

MRNA: Moderna, Inc. Revenue and Sales Volume 07/04/2022 - 11/15/2026

Analytical breakdowns for Moderna, Inc.

- market price and analyst price targets:

Market Price Moderna, Inc.|MRNA - Analyst Consensus Forecast

- market capitalization indicators:

Market Valuation Moderna Therapeutics|MRNA - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Price of a Share Moderna|MRNA - Book Capitalization|Market Capitalization to Book Value modernatx.com|MRNA - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

MRNA - Net Profit|Net Profit Forecast Moderna, Inc.|MRNA - P/E Multiple|Projected Price to Earnings Ratio Moderna Inc|MRNA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Moderna Corp|MRNA - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Moderna|MRNA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth modernatx.com|MRNA - Net earnings per share growth this year|Expected earnings per share trend next year Moderna, Inc.

- company sales and revenue statistics:

MRNA - Revenue and Sales Volume|Company Future Sales modernatx.com|MRNA - Price-to-Revenue Ratio|Market Cap to Projected Revenue Moderna Inc

Comprehensive company analysis:Moderna, Inc.

Original product of Moderna Therapeutics

This metric captures an objective inflow of cash from customers, confirming the current investment security of Moderna, Inc. (MRNA). Product sales dynamics allow for the real-time monitoring of business model resilience without time lags. The calculation is based on daily revenue volume, eliminating the risk of overpaying for the asset. Current levels reflect a decline in demand for pandemic-related drugs. This highlights a temporary weakening of the defensive moat of Moderna, Inc. (MRNA) amid prolonged regulatory reviews of new vaccines.

Analysis of competing companies